Open AccessInfluence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
Author(s) -
Flávia Bittar Britto Arantes,
Fernando Menezes,
André Franci,
Camila de Souza Barbosa,
Talia Falcão Dalçóquio,
Carlos Alberto Kenji Nakashima,
Luciano Moreira Baracioli,
Remo H M Furtado,
Quintiliano Siqueira Schroden Nomelini,
José Antônio Franchini Ramires,
Roberto Kalil Filho,
José Carlos Nicolau
Publication year - 2019
Publication title -
advances in therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.097
H-Index - 62
eISSN - 1865-8652
pISSN - 0741-238X
DOI - 10.1007/s12325-019-01153-8
Subject(s) - medicine , dabigatran , aspirin , platelet , platelet activation , antiplatelet drug , anesthesia , coronary artery disease , cardiology , thromboxane , atrial fibrillation , direct thrombin inhibitor , pharmacology , clopidogrel , warfarin
The interaction between anticoagulants and platelet function is complex. Previous publications showed mixed results regarding the role of heparins in platelet aggregation. On the other hand, the direct thrombin inhibitor (DTI) dabigatran might enhance the risk of myocardial infarction in patients with atrial fibrillation, which could be related to increased platelet aggregability.